Key facts
- It has raised $94.5M; the latest was Early Stage VC ($30.0M) in Aug 2025.
- Notable investors include Alexandria Venture Investments, OrbiMed, SV Health Investors, Euclidean Capital, Chugai Venture Fund — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Leal Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Leal Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Leal Therapeutics
Developer of novel therapeutic services based in Massachusetts. The company offers therapeutics for major central nervous system indications with urgent and unmet needs, enabling patients with precision medicines.
- Sector
- Healthcare
- HQ
- Worcester, MA, United States
- Founded
- 2021
- Employees
- 32
- Website
- lealtx.com/
- Ownership
- Privately Held (backing)
Leal Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Leal Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Leal Therapeutics in its N-PORT filings yet. We sweep new filings monthly.